Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect

Yijun SHEN; Yanhao WANG

doi:10.16016/j.1000-5404.202106156

您当前的位置：

首页 >

文章列表页 >

Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect

Monographic Reports: Basic and clinical researches on bladder cancer | 更新时间：2026-01-09

- Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect
- Journal of Third Military Medical University Vol. 43, Issue 23, Pages: 2507-2511(2021)
- 作者机构：
  
  200032 上海，复旦大学：附属肿瘤医院泌尿外科，上海医学院肿瘤学系
- 作者简介：
- 基金信息：
  
  the Project of Three-Year Action Plan for Promoting Clinical Skills and Innovation Ability of Shanghai Hospital Development Center(SHDC2020CR4031)
- DOI：10.16016/j.1000-5404.202106156
  CLC： R730.5;R737.14
- Received：20 June 2021，
  
  Revised：2021-10-14，
  
  Published：15 December 2021
- 稿件说明：
移动端阅览
Yijun SHEN, Yanhao WANG. Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect[J]. Journal of Third Military Medical University, 2021, 43(23): 2507-2511.
DOI：

Yijun SHEN, Yanhao WANG. Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect[J]. Journal of Third Military Medical University, 2021, 43(23): 2507-2511. DOI： 10.16016/j.1000-5404.202106156.

摘要

大部分高危非肌层浸润性膀胱癌(non-muscle invasive bladder cancer，NMIBC)患者会接受经尿道膀胱肿瘤电切术，然后辅以卡介苗(Bacillus Calmette-Guerin，BCG)膀胱灌注治疗。但不可避免地，一部分患者不能接受卡介苗治疗或者卡介苗治疗失败。因此，根治性膀胱切除术成为唯一的选择。近年来免疫治疗、靶向治疗等方法在膀胱肿瘤治疗领域发展迅速。本文总结了目前高危NMIBC的定义、临床特点和治疗方式，回顾目前高危NMIBC患者的治疗进展，包括BCG治疗失败后新型治疗药物的探索等，提出当前治疗高危NMIBC面临的挑战，并对未来诊疗提出对策和展望。

Abstract

Most patients with high-risk non-muscle invasive bladder cancer (NMIBC) undergo transurethral resection of bladder tumor followed by intravesical adjuvant immunotherapy with Bacillus Calmette-Guerin (BCG). But inevitably

some patients can not receive BCG treatment or are doomed to fail BCG-therapy

consequently. So radical cystectomy becomes only treatment option available. In recent years

immunotherapy and targeted therapy have developed rapidly in the field of bladder tumor. In this article

we summarize the current definition

clinical features and treatment of high-risk NMIBC

review the current treatment progress

including the exploration of new therapeutic drugs after BCG treatment failure

and put forward the current challenges in the treatment and propose countermeasures and prospects for the future diagnosis and treatment of high-risk NMIBC.

关键词

Keywords

references

SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

BABJUK M, BURGER M, COMPÉRAT E M, et al . European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ )-2019 update[J ] . Eur Urol, 2019, 76(5): 6 39-657. DOI: 10.1016/j.eururo.2019.08.016..

TAN W S, RODNEY S, LAMB B, et al . Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia[J ] . Cancer Treat Rev, 2016, 47: 22-31. DOI: 10.1016/j.ctrv.2016.05.002.

CANTER D, EGLESTON B, WONG Y N, et al . Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis[J ] . Urol Oncol, 2013, 31(6): 866-870. DOI: 10.1016/j.urolonc.2011.07.009.

PANG K H, NOON A P. Re: radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study[J]. Eur Urol, 2018, 73(4): 636. DOI: 10.1016/j.eururo.2017.12.007.

KAMAT A M, SYLVESTER R J, BÖHLE A, et al . Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group[J ] . J Clin Oncol, 2016, 34(16): 1935-1944. DOI: 10.1200/jco.2015.64.4070.

BALAR A V,KAMAT A M, KULKARNI G S, et al . Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study[J ] . Lancet Oncol, 2021, 22(7): 919-930. DOI: 10.1016/s1470-2045(21)00147-9.

SINGH P, CATHERINE T, LERNER S P, et al . S1605: Phase Ⅱ trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer[J ] . J Clin Oncol, 2017, 35(15_suppl): TPS4591. DOI: 10.1200/jco.2017.35.15_suppl.tps4591.

LORIOT Y, NECCHI A, PARK S H, et al . Erdafitinib in locally advanced or metastatic urothelial carcinoma[J ] . N Engl J Med, 2019, 381(4): 338-348. DOI: 10.1056/nejmoa1817323.

NECCHI A, RAGGI D, GIANNATEMPO P, et al . Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study[J ] . Eur Urol Oncol, 2020. [Epub ahead of print ] . DOI: 10.1016/j.euo.2020.04.005.

WOODCOCK V K, PURSHOUSE K, BUTCHER C, et al . A phase Ⅰ study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC)[J ] . J Clin Onco l, 2019, 37(7_suppl): 406. DOI: 10.1200/jco.2019.37.7_suppl.406.

YIP W, ASHRAFI A, DANESHMAND S. High-grade T1 urothelial carcinoma: where do we stand? [J]. Curr Urol Rep, 2019, 20(12): 79. DOI: 10.1007/s11934-019-0945-x.

BOORJIAN S A, ALEMOZAFFAR M, KONETY B R, et al . Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial[J ] . Lancet Oncol, 2021, 22(1): 107-117. DOI: 10.1016/s1470-2045(20)30540-4.

BREE K K, BROOKS N A, KAMAT A M. Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer[J]. Hematol Oncol Clin North Am, 2021, 35(3): 513-529. DOI: 10.1016/j.hoc.2021.02.003.

LI R, ZHANG J S, GILBERT S M, et al . Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer[J ] . Nat Rev Urol, 2021, 18(9): 543-555. DOI: 10.1038/s41585-021-00483-z.

PACKIAM V T, LAMM D L, BAROCAS D A, et al . An open label, single-arm, phase Ⅱ multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in pa tients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results[J ] . Urol Oncol, 2018, 36(10): 440-447. DOI: 10.1016/j.urolonc.2017.07.005.

PATEL A, BISNO D I, PATEL H V, et al . Immune checkpoint inhibitors in the management of urothelial carcinoma[J ] . J Cancer Immunol(Wilmington), 2021, 3(2): 115-136. DOI: 10.33696/cancerimmunol.3.047.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Emerging advances in clinical diagnosis and treatment of hepatocellular carcinoma: evolution of comprehensive treatment strategies

Efficacy and safety of immunotherapy combined with targeted therapy and chemotherapy in third-line treatment of microsatellite stable metastatic colorectal cancer

Development and validation of clinical prediction model for post-treatment recurrence in high-risk non-muscle invasive bladder cancer after BCG intravesical instillation

A2G plus management model for Alzheimer’s disease

Effects of PRKCH on CD8+T cell function and melanoma immunotherapy

Related Author

WANG Xingru

LI Jianwei

SONG Jian

ZHAO Wensi

RAN Qiang

ZHANG Jian

CHEN Jian

LUO Weiming

Related Institution

Institute of Hepatobiliary Surgery of PLA，First Affiliated Hospital， Army Medical University （Third Military Medical University）

No.953，Xigaze， Tibet Autonomous Region

Department of Oncology, Renmin Hospital of Wuhan University

Department of Pharmacy, Renmin Hospital of Wuhan University

Department of Urology， Army Medical Center of PLA/Daping Hospital of Third Military Medical University

⁰